评估基于英克雷丁的治疗对下丘脑肥胖症的有效性和潜在机制:叙述性综述
Dionysios V Chartoumpekis1, Evagelia E Habeos2, Aristea Psilopanagioti2
1Service of Endocrinology, Diabetology and Metabolism, Lausanne University Hospital and University of Lausanne, CH-1011, Lausanne, Switzerland.
Obesity pillars
|March 11, 2024
概括
类似葡萄糖类-1 (GLP-1) 受体激动剂在下丘脑肥胖症治疗中表现有前途. 需要进一步的研究来证实疗效,并了解这种疾病的大脑GLP-1受体的功能.
科学领域:
- 内分泌学 在内分泌学.
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 脑下垂体肥胖症是一种诊断不足的疾病,缺乏预测标志物和标准化治疗方法.
- 葡萄糖类-1 (GLP-1) 受体激活剂正在成为潜在的肥胖治疗方法.
- 它们在下丘脑肥胖症中的疗效和机制需要进一步研究.
研究的目的:
- 审查关于大脑GLP-1受体表达的文献,以及在下丘脑肥胖症中使用GLP-1受体激动剂.
- 分析当前的证据,并确定关于这种治疗方法的知识差距.
主要方法:
- 关于在下丘脑和大脑区域中GLP-1受体检测和功能的研究论文的叙述性综述.
- 检查临床研究和病例报告,以GLP-1受体激动剂治疗下丘脑肥胖症.
- 包含一个临床病例介绍,用于上下文说明.
主要成果:
- 临床证据表明GLP-1受体激动剂在下丘脑肥胖症中的有效性目前有限.
- 初步数据表明潜在的益处,特别是在年轻患者中,但结果各不相同.
- GLP-1受体存在于与肥胖相关的大脑区域,这表明即使在下丘脑损伤的情况下也可能存在作用机制.
结论:
- GLP-1受体激动剂可能为下丘脑肥胖症提供治疗选择.
- 更多的临床和转化研究是必要的,以验证在各种呈现的有效性和阐明受体功能在大脑.
相关概念视频
Glucagon-like Receptor Agonists
321
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
Dipeptidyl Peptidase 4 Inhibitors
186
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
186
Oral Hypoglycemic Agents: Biguanides and Glitazones
199
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
199
Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
175
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
175
Regulation of Food Intake
228
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
228


